Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $23.80 Consensus Target Price from Analysts

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have been assigned an average recommendation of "Buy" from the six ratings firms that are covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $23.80.

Several research analysts have commented on LXEO shares. Chardan Capital raised their price target on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Leerink Partners cut their price target on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an "outperform" rating for the company in a report on Wednesday, November 13th. HC Wainwright raised their price target on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the company a "buy" rating in a report on Thursday, November 14th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $24.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday, January 21st.

Lexeo Therapeutics Stock Performance

Shares of LXEO stock traded up $0.28 during trading on Tuesday, reaching $4.50. 252,794 shares of the company's stock traded hands, compared to its average volume of 258,523. The company has a market capitalization of $148.82 million, a P/E ratio of -1.42 and a beta of 2.99. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm's 50-day moving average is $6.10 and its 200 day moving average is $8.41. Lexeo Therapeutics has a 1 year low of $3.84 and a 1 year high of $19.50.

Hedge Funds Weigh In On Lexeo Therapeutics

Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its position in Lexeo Therapeutics by 86.5% in the 3rd quarter. Geode Capital Management LLC now owns 553,247 shares of the company's stock worth $5,003,000 after purchasing an additional 256,635 shares during the period. State Street Corp raised its position in Lexeo Therapeutics by 29.4% in the 3rd quarter. State Street Corp now owns 253,946 shares of the company's stock worth $2,296,000 after purchasing an additional 57,674 shares during the period. Frazier Life Sciences Management L.P. purchased a new position in Lexeo Therapeutics in the 3rd quarter worth $11,307,000. Barclays PLC raised its position in Lexeo Therapeutics by 162.2% in the 3rd quarter. Barclays PLC now owns 50,210 shares of the company's stock worth $454,000 after purchasing an additional 31,057 shares during the period. Finally, Janus Henderson Group PLC raised its position in Lexeo Therapeutics by 18.9% in the 3rd quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company's stock worth $33,997,000 after purchasing an additional 599,203 shares during the period. Hedge funds and other institutional investors own 60.67% of the company's stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.